Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00418600 · ClinicalTrials.gov registry record · Phase 4

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

A Phase 4 study of Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company.

Completed
Registry status
Phase 4
Development phase
36
Enrollment target
8
Study locations

NCT00418600: Completed Phase 4 study of Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company.

NCT00418600 is a Phase 4 study of Secondary Hyperparathyroidism that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 36 participants, below the 60-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (40% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00418600, a Phase 4 study of Secondary Hyperparathyroidism, has completed, sponsored by Genzyme, a Sanofi Company.

COMPLETED
Registry status
Phase 4
Development phase
36 participants
Enrollment target
8
Study locations

Study Summary

Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease. Hectorol (doxercalciferol injection) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. This protocol will determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting subject from Hectorol (doxercalciferol injection.) The study will enroll hemodialysis patients that have been controlled on intravenous Hectorol. the information gained from this study will be a useful guide for physicians in managing CKD Stage 5 patients for whom a change from intravenous to oral vitamin D administration is appropriate.

Conditions Studied

Secondary Hyperparathyroidism

Interventions

  • DRUG Hectorol® (doxercalciferol capsules)
  • DRUG doxercalciferol capsules, Hectorol®
  • DRUG doxercalciferol capsules, Hectorol® capsules

Study Locations (8)

California

  • - Downey
  • - Tarzana

Arkansas

  • - Hot Springs

Georgia

  • - Atlanta

Ohio

  • - Cincinnati

Pennsylvania

  • - Pittsburgh

Texas

  • - Houston

Washington

  • - Spokane

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2006-11
Est. Completion 2007-08
Phase Phase 4
Genzyme, a Sanofi Company

196 total trials

What the finished NCT00418600 record still lists

NCT00418600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (40% lower).

The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 3 interventions - of which Hectorol® (doxercalciferol capsules) is the first listed.

NCT00418600 lists 8 locations in 7 states (California, Arkansas, Georgia).

Frequently Asked Questions

What is clinical trial NCT00418600 about?

NCT00418600 is a clinical study titled "A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis". Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with Stage 3 or S...

What is the current status of trial NCT00418600?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2006-11. Estimated completion is 2007-08.

What conditions does trial NCT00418600 study?

This clinical trial studies the following conditions: Secondary Hyperparathyroidism.

What interventions are being tested in trial NCT00418600?

The interventions under investigation include: Hectorol® (doxercalciferol capsules) (DRUG), doxercalciferol capsules, Hectorol® (DRUG), doxercalciferol capsules, Hectorol® capsules (DRUG).

Who is sponsoring clinical trial NCT00418600?

This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00418600 being conducted?

This trial has 8 study locations across Arkansas, California, Georgia, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Secondary Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00418600's enrollment target sits among peer trials

36 8th of 8 higher than 1 of 8 other Secondary Hyperparathyroidism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Secondary Hyperparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00418600, the US trial registry maintained by the National Library of Medicine. NCT00418600 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.